RGT
Argent Biopharma Limited
π¦πΊ ASX
π¦ LOGISTICS
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
+ 105.93%
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
6
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Argent Biopharma Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2006-12-21. Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The firm is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.
π Performance
Price History
+4150.00%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$0.17
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in RGT
6
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in RGT
87 days
RGT investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
17%
100k - 150k
33%
50k - 100k
33%
Less than 50k
17%
πΆ Age of investors
18 - 25
26 - 34
17%
35 - 90
83%
π Legal gender of investors
Female
50%
Male
50%
Pearlers who invest in RGT also invest in...
MGC Pharmaceuticals Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. MGC Pharmaceuticals Ltd is an Australia-based biopharma company. The firm is primarily focused on the development and supply of standardized phytomedicines to patients globally. The company has three clinical projects, as well as a pipeline of therapies: CimetrA, a Phase III symptomatic treatment for early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant Epilepsy; CogniCann, in a Phase II trial for symptomatic relief of Dementia, and Irnican, a preclinical medicine to be used for treatment for Glioblastoma. The firm is focused on the ArtemiC range of products, and its cannabinoid products are primarily distributed within Australia, the United Kingdom and South America. The company has a product offering targeting two medical conditions, which include epilepsy and dementia. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.
π Share price
$0.42 AUD
NULL STOCK
MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its central business strategy revolves around the development and supply of medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia. The company maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products in the developmental stages. Its clinical trials include CannEpil, CimetrA and ArtemiC. The company has a growing patient base in Australia, the United Kingdom, Brazil, and Ireland. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.
π Performance (5Yr p.a)
220.00%
π Share price
$0.42 AUD
π¦ LOGISTICS
Liontown Resources Ltd. engages in the exploration and evaluation of minerals. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-27. The firm controls two major hard rock lithium deposits. The firm's projects include Kathleen Valley Project and Buldania Project. The Kathleen Valley Project is located in an established mining region about 60 kilometers north of Leinster and 680 kilometers north-east of Perth, Western Australia. The Kathleen Valley Lithium Project is a Tier-1 battery metals asset with excellent grade and scale in one of world's best mining districts. The Buldania Project is in the Eastern Goldfields Province of Western Australia, approximately 600 kilometers east of Perth. The Project is close to major road and rail infrastructure with direct access to the Port of Esperance 200 kilometers to the south. The firm's downstream expansion project includes investigating the potential for an integrated refinery to upgrade its spodumene from the Kathleen Valley mine to higher value lithium products.
π Performance (5Yr p.a)
95.53%
π Share price
$0.61 AUD
βοΈ MINING
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
12.60%
π Share price
$140.89 AUD
π€ TECHNOLOGY
π GLOBAL
β³οΈ DIVERSIFIED
π HIGH PRICE GROWTH
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6966.81m in AUM and 201 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
π Performance (5Yr p.a)
3.43%
π Share price
$136.88 AUD
πΈ FINANCIALS
π¦πΊ AUSTRALIA
β³οΈ DIVERSIFIED
Want more shares? Try these...
RGS
Regeneus Ltd. is regenerative medicine company. The firm uses stem cell technologies to develop a portfolio of novel cell-based therapies. The firm develops regenerative medicine products, including its two stem cell technologies, Progenza, which has been licensed to Kyocera for the treatment of knee osteoarthritis in Japan, and Sygenus, which is in pre-clinical-stage. Regenerative therapies seek to address unmet medical needs in the human health market, focusing on osteoarthritis, neuropathic pain, and various skin conditions, with its platform technologies Progenza and Sygenus. Progenza is a cellular therapy targeting pain and inflammation which uses Secretome to improve not only the resident tissue, but the Mesenchymal Signalling Cells (MSCs) themselves. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation.
π Performance (5Yr p.a)
-17.54%
π Share price
$0.01 AUD
𧬠BIOTECHNOLOGY